TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure.
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Regulation FD Disclosure
Charles P. Theuer, M.D., Ph.D., and other executive officers will be presenting the information attached as Exhibit 99.1 to this Current Report on Form 8-K at various upcoming meetings beginning April 23, 2018.
By furnishing this information, TRACON makes no admission as to the materiality of any information in this report and the exhibit hereto. The information contained in this report and the exhibit hereto is intended to be considered in the context of TRACON’s filings with the Securities and Exchange Commission and other public announcements that TRACON makes, by press release or otherwise, from time to time. TRACON undertakes no duty or obligation to publicly update or revise the information contained in this report or the exhibit hereto, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosure.
|
Item 7.01 |
Financial Statements and Exhibits. |
|
Exhibit No. |
Description |
|
99.1 |
Corporate Presentation, dated April 2018 |
Tracon Pharmaceuticals, Inc. ExhibitEX-99.1 2 tcon-ex991_6.htm EX-99.1 tcon-ex991_6.pptx.htm TRACON PHARMACEUTICALS April 2018 NASDAQ: TCON Exhibit 99.1 This presentation contains statements that are,…To view the full exhibit click here
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.
